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Segmental volumes analysis of the liver: neither segments nor patients
are equal
The technology used to measure liver volume continues to improve and with it our understanding of
liver anatomy in relation to surgery. In this month’s issue of HPB, Kokudo’s group from Tokyo present
an analysis of single segment volumes of the livers of more than 100 patients. This detailed analysis was
performed based on portal perfusion patterns to define segmental anatomy. The authors have produced
a volume ‘road map’ of the liver demonstrating typical segmental volumes for each of the eight liver
segments. On the face of it this information is extremely valuable for the surgeon, however, what this
study also shows is the very major variation in segmental volumes that occur between different patients.
An example of this is given by the data for segment VIII. This segment had the largest mean volume of
functional liver accounting for on average 26% of total liver volume (TLV),however this ranged between
individual patients from only 11% to as much as 38% of TLV. The message here is that individual patient
assessment remains critical to pre-operative planning. Among the liver surgical community opinion is
divided over how much anatomical planning is required in patients. There are clearly patients who may
have precarious liver function or difficultly placed tumours where careful anatomical staging and
volume analysis are imperative to successful outcome. Equally there are many others where standard
anatomical resection is unlikely to compromise either resection margins or functional capacity of the
liver. In those cases where planning is required, measurement of portal perfusion territories seems to
offer the best basis for anatomical staging and volume assessment.
Stephen J Wigmore
Check it and get better
Despite the introduction of the World Health Organization surgical safety checklist and it being
credited with significant reduction in morbidity and mortality, there continues to be concern regard-
ing the elimination of surgical error during routine surgery. This is no better demonstrated than in the
setting of gallbladder surgery. Despite numerous attempts to highlight the key elements required to
perform safe laparoscopic cholecystectomy since its introduction into clinical practice, bile duct injury
remains a significant source of risk to the patient. Connor and his colleagues have sought to pull
together the key manoeuvres required to perform safe cholecystectomy and incorporate these into an
operative checklist. Its simplicity provides the surgeon with a defined standard approach which should
ensure that bile duct injury is a ‘never event’. This uncomplicated checklist should facilitate engage-
ment of team members with the procedure and engender a culture of safety in the operating room.
There is an opportunity and responsibility for all surgeons undertaking laparoscopic cholecystectomy
to assess this checklist and defy the authors’ belief that this approach should eliminate the risk of bile
duct injury. We may all believe that we are very good at what we do, but we can be even better.
James Garden
Utility of CA 19-9 following Neoadjuvant Therapy in Pancreatic Cancer
Serum carbohydrate antigen (CA) 19-9 is the best tumour marker available today in the management
of patients with pancreatic adenocarcinoma (PDAC). In studies evaluating its value in resectable and
unresectable PDAC, the strengths and weaknesses of CA 19-9 have become apparent. Tzeng et al. now
evaluate its utility as relates to oncologic and survival outcomes following multimodality neoadjuvant
therapy (NT) in borderline resectable (BR) PDAC patients. Of 141 eligible patients evaluated over 10
years, CA 19-9 levels declined during NT in 116. Jaundiced patients were properly excluded in the
analysis. Resection was ultimately possible in 84 (60%) of these 141 patients following NT. An actual
normalization of CA 19-9 after NT was associated with longer median overall survival in both resected
and non-resected patients. If CA 19-9 increased during NT, subsequent resection was infrequent (3/25
patients). After detailing the positive and negative predictive values of CA 19-9 trends with NT, the
authors justifiably endorse its value in guiding therapy for BR-PDAC, an especially vulnerable subset
of patients. While CA 19-9 still cannot reliably direct all decision-making in patients with PDAC, this
paper further supports its utility as an actionable surrogate biomarker. Perhaps someday we will have
an inexpensive, convenient and reliable biomarker to serve all purposes, even to the dream of early
PDAC detection through population screening. But, being so far from that day, CA 19-9 remains the
best we have.
Mark Callery
Rouvière's 
sulcus 
segment VIII
segment V
HPB
